MAX KUPFERMAN: Open Payments
NPI 1629643028 · NEWPORT BEACH, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,500 in 99 payments from 22 companies in 2025. Trend: 2023 $2,614 · 2024 $2,755 · 2025 $2,500
Food & beverage: $2,500
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 12 | $355 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $348 |
| Vanda Pharmaceuticals Inc. | 9 | $289 |
| Janssen Pharmaceuticals, Inc | 7 | $219 |
| Otsuka America Pharmaceutical, Inc. | 8 | $200 |
| Bausch Health US, LLC | 6 | $133 |
| E.R. Squibb & Sons, L.L.C. | 4 | $119 |
| Teva Pharmaceuticals USA, Inc. | 6 | $117 |
| Axsome Therapeutics, Inc. | 4 | $99 |
| LivaNova USA, Inc. | 1 | $88 |
Products named: INGREZZA, CAPLYTA, HETLIOZ, SPRAVATO, ABILIFY ASIMTUFII, APLENZIN, REXULTI, COBENFY.
Industry payments across CA — which companies pay providers there.
